Drugs / KP-100LI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05627648 Comparator | Dec 2022 → Jul 2026 overdue | — | Kringle Pharma, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KP-100LI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05627648 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human dHGF as the active pharmaceutical ingredient” NCT05627648 ↗ |
| Route | Other | “Intracordal injection, 20 mcg once per week, 3 weeks” NCT05627648 ↗ |